PMID: 9174199Jun 1, 1997Paper

Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model

Antimicrobial Agents and Chemotherapy
M J RybakG W Kaatz

Abstract

We evaluated the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against fibrin-platelet clots (FPC) infected with two clinical isolates of Staphylococcus aureus, one constitutively erythromycin and methicillin resistant (S. aureus AW7) and one erythromycin and methicillin susceptible (S. aureus 1199), in an in vitro pharmacodynamic infection model. RP 59500 was administered by continuous infusion (peak steady-state concentration of 6 microg/ml) or intermittent infusion (simulated regimens of 7.5 mg/kg of body weight every 6 h (q6h) q8h, and q12h. FPCs were infected with S. aureus to achieve an initial bacterial density of 10(9) CFU/g. Model experiments were run in duplicate over 72 h. Two FPCs were removed from each model at 0, 12, 24, 36, 48, and 72 h, and the bacterial densities (in CFU per gram) were determined and compared to those of growth control experiments. Additional samples were also removed from the model over the 72-h period for pharmacokinetic evaluation. All regimens significantly (P < or = 0.01) decreased bacterial densities in the infected FPCs for both isolates compared to growth controls. This occurred even though MBCs were equal to or greater than the RP 59500 concentrations achieved in the mo...Continue Reading

References

Jul 1, 1992·The Journal of Antimicrobial Chemotherapy·A NougayredeD H Bouanchaud
Jul 1, 1992·The Journal of Antimicrobial Chemotherapy·S D EtienneJ J Garaud
Jul 1, 1992·The Journal of Antimicrobial Chemotherapy·W BrumfittS Shah
Oct 1, 1992·Antimicrobial Agents and Chemotherapy·A C Cremieux, C Carbon
Jul 1, 1991·Antimicrobial Agents and Chemotherapy·R Leclercq, P Courvalin
Dec 1, 1988·Drug Intelligence & Clinical Pharmacy·D F ThompsonG D Thompson
Apr 1, 1970·Applied Microbiology·H J Simon, E J Yin
Jun 1, 1983·Computer Programs in Biomedicine·M L Rocci, W J Jusko
Oct 1, 1995·The Annals of Pharmacotherapy·C Chant, M J Rybak
Oct 1, 1995·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·D E Low

❮ Previous
Next ❯

Citations

Aug 21, 2002·Expert Opinion on Pharmacotherapy·Joseph M Blondeau, Stephen E Sanche
Aug 11, 2004·American Journal of Clinical Dermatology·Iain B Gosbell
Nov 21, 2001·Pharmacotherapy·B W GundersonJ C Rotschafer
Jun 25, 2004·Antimicrobial Agents and Chemotherapy·Renee-Claude MercierMichael R Yeaman
Apr 24, 2003·Antimicrobial Agents and Chemotherapy·Carole J BoylanThomas R Parr

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.